Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF

Edimar Alcides Bocchi,1,2,3 Andréa Bioso,1,2,3,4 Lidia Zytynski Moura,5 José Albuquerque Figueiredo Neto,6,9 Carlos Eduardo Lucena Montenegro,7,8 Denilson Campos de Albuquerque2,3,4

Possible Mechanisms of Action

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) inhibit glucose reabsorption in proximal convoluted tubules, resulting in glycosuria and reduced blood glucose levels. However, this effect does not seem to explain the benefits of SGLT2i in patients with heart failure (HF).1,2

Its benefits also do not seem to be directly related to its effects on classic cardiovascular risk factors (SAH, DM, DLP), since outcome reduction in the EMPA-REG study was not dependent on the baseline metabolic/hemodynamic profile of the patients or their variation throughout the study.1

One of the most accepted mechanisms for explaining the mode of action of SGLT2i in HF is improved parietal tension of the left ventricle secondary to a decrease in pre-effect of natriuresis and osmotic diuresis) and afterload (improvement in endothelial function and reduction of blood pressure).4,6 Metabolic mechanisms include improved cardiomyocyte metabolism and bioenergetics (increased ketogenesis and increased β-hydroxybutyrate levels),7 myocardial sodium-hydrogen pump inhibition (which leads to a higher concentrations of calcium in the mitochondria),8 reduced cardiac necrosis and fibrosis (inhibition of collagen synthesis)9 and changes in cytokine production and epicardial fatty tissue.10

However, there are still questions about the real contribution of these mechanisms.

Their benefits exist with or without DM, which calls the role of ketogenesis into question.

Keywords

heart failure; SGLT2i.

Research Letter

New evidence about HF prevention

The first large study on this therapeutic class (EMPA-REG OUTCOME) was published in 2015.12 It evaluated empagliflozin in DM2 patients with established cardiovascular disease who were receiving normal treatment. Among those who received empagliflozin, there was a significant reduction in major adverse cardiovascular events (MACE: CV death, non-fatal MI or non-fatal stroke) (hazard ratio [HR]: 0.86 95% CI: 0.74-0.99) and a surprising reduction in hospitalization for HF (HHF) (HR: 0.65 [95%CI: 0.50-0.85]. The CANVAS Program,11 published in 2017, evaluated canagliflozin in DM2 patients with a high risk of cardiovascular events who were receiving normal treatment. It found a reduction in the combined primary endpoint (MACE: CV death, non-fatal MI or non-fatal stroke) and a 33% reduction in HHF (HR = 0.67, 95%CI: 0.52-0.87), as well as fewer combined renal events.

The DECLARE-TIMI 58 trial14 evaluated dapagliflozin in DM2 patients with established atherosclerotic disease or multiple risk factors for atherosclerotic disease who were receiving normal treatment. There was no reduction in the combined primary outcome (MACE: CV death, MI or stroke). There was a 17% reduction in the combined outcome of cardiovascular mortality and HHF, and a 27% reduction (HR: 0.73 [95%CI: 0.61-0.88]) in HHF. More recently, the VERTIS–CV trial15 evaluated etrugliflozin (not yet marketed in Brazil) in DM2 patients with established cardiovascular disease who were receiving normal treatment. Although there was no reduction in the combined primary outcome (MACE: CV death, myocardial infarction or stroke), a 30% reduction in HHF was observed.

Taken together, the available data demonstrate the effectiveness of SGLT2i for reducing the incidence of HF in groups of DM2 patients.
When assessed in isolation, the other outcomes showed benefits for the group that received the medication. For the combined outcome of cardiovascular mortality and HHF, the HR of HHF was 0.73 (95% CI: 0.61-0.88) and the HR was 0.83 (95% CI: 0.73-0.95). For renal failure or mortality, the HR was 0.53 (95% CI: 0.43-0.66).

There was a HR of 0.86 (95% CI: 0.74-0.99) for the results for the combined primary outcome (MACE: CV death, non-fatal MI or non-fatal stroke).

New evidence about HF treatment in patients with and without DM

**HF prevention in diabetics**

HF is the second leading cause of cardiovascular disease in DM2. The prevalence of HF is 9-22%, which is four times the prevalence in the general population and is generally higher in females (relative risk reduction (RRR) 1.95 vs. 1.75). Recent data suggest that, in DM2 patients, body mass index has a greater impact on the development of HF than glycated HB itself, which is unlike the AMI/stroke outcome.

Therefore, the different mechanisms of hypoglycemic drugs should be considered for this outcome in general, not just for glycemic control. It has been shown that DPP-4 inhibitors are a neutral class in all aspects of cardiovascular disease. As a class, GLP1 agonists reduced the risk of atherosclerotic cardiovascular disease (reduced AMI and/ or stroke). However, SGLT2i showed a definite benefit by reducing HHF. Recently, the DAPA-HF and EMPEROR-Reduced trials demonstrated increased benefits in HF patients (both diabetic and non-diabetic) with reduced ejection fraction. These studies found that, as an add-on therapy to pharmacological treatment optimized for HF, SGLT2i reduced HHF and cardiovascular mortality.

Thus, a meta-analysis of combinations demonstrated that a potential ideal treatment regimen with reduced CV and HF outcomes could be a combination of GLP1-a and SGLT2i in a history of metformin therapy.

**SGLT2i in ICFER - which, for whom, and when**

In the VERTIS-CV trial, SGLT2i (ertugliflozin) reduced hospitalization for HF in diabetic patients with vascular disease due to atherosclerosis. In the EMPEROR-Reduced trial, SGLT2i (empagliflozin) reduced the combined primary outcome of HHF/cardiovascular death and the secondary outcomes HHF and decline in renal function, as well as improved quality of life, reduced glycated hemoglobin and NT-proBNP.

In the DAPA-HF trial, dapagliflozin reduced the combined outcome of hospitalization/urgent visit due to HF and cardiovascular death, the secondary outcomes cardiovascular death/HHF, total HHF/cardiovascular death, all-cause mortality, and improved quality of life. Likewise, in the DECLARE-TIMI trial, dapagliflozin reduced renal events, while in the DAPA-CKD trial it reduced the risk of sustained decline in renal function in patients with chronic kidney
disease, whether diabetic or not. Subanalysis of the DAPA-HF trial showed reduced progression of renal function decline in HF patients, while pre-specified analysis of the EMPA-REG OUTCOME trial showed that SGLT2i (empagliflozin) reduced the progression of renal function decline in diabetics. Finally, in the CREDEANCE trial, canagliflozin reduced the progression of renal function decline.

Figure 2 summarizes the unquestionable benefits of SGLT2i (i.e. reduced hospitalization) presented in the main studies.

The most recent SBC Brazilian Heart Failure guideline, coordinated by the Department of Heart Failure (DHF), was published in 2018 and little was known about the role of iSGLT2 in the therapeutic management of HF. It was a consensus in the DHF that the time had come to revisit it. For that purpose, preparatory meetings were held, topic divisions were made among the different collaborators and a virtual meeting took place on December 4, 2020, due to the COVID-19 pandemic. This meeting was attended by renowned experts in the HF area, who provided updates, offered their opinions and included new therapeutic options. The iSGLT2 have been incorporated into the therapeutic management of HF, gathered together in a single table that will be published shortly.

List of participants of the Heart Failure Summit Brazil 2020 / Heart Failure Department - Brazilian Society of Cardiology

Aguinaldo Freitas Junior, Andréia Biolo, Antonio Carlos Pereira Barretto, Antônio Lagoéiro Jorge, Bruno Biselli, Carlos Eduardo Lucena Montenegro, Denilson Campos de Albuquerque, Dirceu Rodrigues de Almeida, Edimar Alcides Bocchi, Edval Gomes dos Santos Júnior, Estêvao Lanna Figueiredo, Evandro Tinoco Mesquita, Fabiana G. Marcondes-Braga, Fábio Fernandes, Fabio Serra Silveira, Felix José Alvarez Ramires, Fernando Atik, Fernando Bacal, Flávio de Souza Brito, Germano Emilio Conceição Souza, Gustavo Calado de Aquiári Ribeiro, Humberto Villacorta Jr., Jefferson Luís Vieira, João David de Souza Neto, João Manoel Rossi Neto, José Albuquerque de Figueiredo Neto, Lidia Ana Zytynski Moura, Livia Adams Goldraich, Luís Beck-da Silva, Luís Eduardo Paim Rohde, Luiz Claudio Danzmann, Manoel Fernandes Canesin, Marcelo Bittencourt, Marcelo Westerlund Monteria, Marcely Gimenes Bonatto, Marcus Vinicius Simões, Maria da Consolação Vieira Moreira, Miguel Morita Fernandes da Silva, Monica Samuel Avila, Mucio Tavares de Oliveira Junior, Nadine Clausell, Odilson Marcos Silvestre, Otavio Rizzi Coelho Filho, Pedro Vellosa Schwartzmann, Reinaldo Bulgarelli Bestetti, Ricardo Mourilhe Rocha, Sabrina Fernadez Pereira, Salvador Rassi, Sandrigo Mangini, Silvia Marinho Martins, Silvia Moreira Ayub Ferreira, Victor Sarli Issa.

Author contributions

Writing of the manuscript and Critical revision of the manuscript for intellectual content: Bocchi EA, Biolo A, Moura LZ, Figueiredo Neto JA, Montenegro CEL, Albuquerque DC.

Figure 2 – Reduction in hospitalization for heart failure in SGLT2i studies. RRR: relative risk reduction.
Potential Conflict of Interest

Dr. Edimar Bocchi - Consultancy/lecture fee: Boehringer Ingelheim, Astra Zeneca. Research grant: Astra Zeneca. Research projects: Boehringer Ingelheim, Astra Zeneca.

Dr. Lidia Zytynski Moura - Speaker and advisory board at Astra Zeneca.

Dr. Carlos Eduardo Lucena Montenegro - Speaker at Astra Zeneca.

Dr. José Albuquerque de Figueiredo Neto - Speaker at Astra Zeneca.

References

1. Verna, S., McMurray, J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 2018.

2. Lopaschuk, GD and Verna S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci, 2020; 5(6):632-644.

3. Fitchett D, Inzucchi SE, Cannon CP et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation, 2019; 139(11): 1384–1395.

4. Wanner, C, Lachin JM, Inzucchi SE et al (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137:119–129.

5. Verma S, McMurray JJV, Cherney DZI (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2:939–940.

6. Sattar N, McLaren J, Kristensen SL et al. (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339.

7. Fennanini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME Trial: a “Thrifty Substrate” hypothesis. Diabetes Care 39:1108–1114.

8. Baertscheer A, Schumacher CW, Wust RC et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+ /H+ exchanger in rats and rabbits. Diabetologia 2017; 60:568–573.

9. Fedak PW, Verna S, Weisel RD, Li RK. Cardiac remodeling and failure from molecules to man (part II). Cardiovasc Pathol 2005; 14: 49–60.

10. Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 2018; 20(6):1361-1366.

11. Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol. 2019; 18(1):129.

12. Zinman B, Wanner C, Lachin JM et al. for the EMPA-REG OUTCOME Investigators: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2177-2182

13. Neal B, Perkovic V, Mahaffey KW et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17; 377(7):644-657. doi: 10.1056/NEJMoa1611925

14. Wiviott SD, Raz I, Bonaca MP et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24; 380(4):347-357. doi: 10.1056/NEJMoa1812389

15. Cannon CP, Pratley R, Dagogo-Jack S et al. VERTIS C Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020 Oct 8; 383(15):1425-1435. doi: 10.1056/NEJMoa2004967.

16. Ohkuma T, Komorita V, Peters, SAE. et al. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia 62, 1550–1560 (2019).

17. Rawshani A, Rawshani A, Franzen S, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018; 379(7):633-644. doi:10.1056/NEJMoa1800256

18. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet. 2019 Jan 5; 393(10166);31-39. doi: 10.1016/S0140-6736(18)32590-X

19. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019; 150:8-16. doi: 10.1016/j.diarres.2019.02.014

20. Packer M, Anker SD, Butler J, Bocchi E et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8; 383(15);1413-1424. doi: 10.1056/NEJMoa2022190.

21. McMurray JJV, Solomon SD, Inzucchi SE et al DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21; 381(21);1995-2008. doi: 10.1056/NEJMoa1911303

22. Perkovic V, Jardine MJ, Bocchi EA et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13; 380(24);2295-2306. doi: 10.1056/NEJMoa1811744.

23. Comitê Coordenador da Diretriz de Insuficiência Cardiaca, Rohde LEP, Monteria MW, Bocchi EA, et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol. 2018 Sep;111(3):436-539

This is an open-access article distributed under the terms of the Creative Commons Attribution License